

⑫

EUROPEAN PATENT APPLICATION

⑳ Application number: 88303560.2

⑤① Int. Cl. 4: **A61K 31/20 , A61K 9/28**

㉔ Date of filing: 20.04.88

③① Priority: 27.04.87 GB 8709892
25.08.87 GB 8719988
29.01.88 GB 8802016

④③ Date of publication of application:
02.11.88 Bulletin 88/44

⑥④ Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

⑦① Applicant: **EFAMOL HOLDINGS PLC**
Efamol House Woodbridge Meadows
Guildford Surrey GU1 1BA(GB)

⑦② Inventor: **Horrobin, David Frederick**
2e Cedar Lodge Lythe Hill Park
Haslemere Surrey(GB)

⑦④ Representative: **Cockbain, Julian Roderick**
Michaelson et al
Frank B. Dehn & Co. European Patent
Attorneys Imperial House 15-19, Kingsway
London WC2B 6UZ(GB)

⑤④ **Lithium salt-containing pharmaceutical compositions.**

⑤⑦ The invention provides pharmaceutical and disinfectant compositions containing lithium salts of C₁₈₋₂₂ polyunsaturated fatty acids. The compositions may be used in the treatment of conditions responsive to lithium and/or polyunsaturated fatty acid therapy, in parenteral alimentation or food supplements or in surface disinfection to combat transmission of viral diseases.

to such compositions containing lithium salts or polyunsaturated fatty acids, to the use of such lithium salts in the preparation of pharmaceutical compositions and to therapeutic treatments of the human or non-human body with such lithium salts.

5 The oral and parenteral administration of lithium salts, in particular salts such as lithium carbonate, has found widespread use in the treatment of manic-depressive psychosis. Oral administration of lithium salts conjointly with polyunsaturated fatty acids such as dihomogamma-linolenic acid, gamma-linolenic acid and linoleic acid has also been suggested for use in the treatment of Alzheimer's disease and inflammation and smooth muscle spasm arising from imbalances in the body's prostaglandin levels. Lithium salts have also
10 been used successfully for the topical treatment of viral infections such as genital herpes.

Lithium salt therapy has also been used in or proposed for the treatment of several other conditions, such as for example alcoholism, various dementias, aggression, schizophrenia, unipolar depression, skin disorders (including contact dermatitis, atopic dermatitis, seborrhoeic dermatitis, psoriasis and acne), immunological disorders, asthma, multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis,
15 and irritable bowel syndrome.

Polyunsaturated fatty acids are also known to possess physiological activities, including virucidal activities, and have been used in or proposed for the treatment of conditions such as for example atopic disorders (including eczema, asthma and allergic rhinitis), disorders associated with atopy, (including Crohn's disease, ulcerative colitis, otitis media and nephrotic syndrome), benign diseases of the breast and prostate glands, premenstrual breast disease (cyclical mastalgia), breast, prostatic or other cancers, diabetes and the complications of diabetes (including nephropathy, neuropathy, retinopathy and micro-vascular and macrovascular cardiovascular complications), alcoholism and the complications of alcoholism, psychiatric disorders including schizophrenia, depression and tardive dyskinesia, conditions associated with elevated blood cholesterol and/or triglyceride levels, with elevated blood pressure, with an increased risk of
25 development of thrombotic disorders, with an increased risk of development of coronary heart diseases, with ulcers in the stomach, duodenum or any other part of the gastrointestinal tract, with reflux oesophagitis or irritable bowel syndrome, and with rheumatoid arthritis, osteoarthritis or other diseases associated with inflammation, damage to connective tissue or disordered immune function such as Sjogren's syndrome, Raynaud's syndrome, systemic lupus erythematosus, polyarteritis nodosa, primary biliary cirrhosis, and multiple sclerosis, and diseases of the kidneys including acute and chronic glomerulonephritis, nephrotic syndrome, diabetic nephropathy. Polyunsaturated fatty acids are also used in enteral and parenteral
30 alimentation, e.g. of patients who are to be or have been subjected to surgery. In parenteral alimentation or nutrition however it has not proved to be simple to formulate a single parenterally administrable composition capable of meeting the patient's entire nutritional requirements as although the majority of essential nutrients, e.g. vitamins, minerals and calorie sources, may be formulated in aqueous solution the essential fatty acids, due to their lipid nature, can not.

The difficulties associated with the preparation and administration of homogeneous single phase parenteral nutrition solutions have thus been such that the essential fatty acids have commonly been omitted from such solutions. Consequently where parenteral nutrition has had to be performed over a period
40 so prolonged that omission of the essential fatty acids could not be tolerated it has been necessary to administer the essential fatty acids separately, as lipid emulsions, and in practice problems have been encountered and dangers (e.g. of fat embolism) have been foreseen with such parenteral administration of lipid emulsions, especially to infants.

Thus, solutions for long term parenteral nutrition typically contain ingredients such as essential amino
45 acids, proteins, glucose and/or other carbohydrates, sodium, potassium, calcium, magnesium, chloride, acetate, phosphate, zinc, copper, iodine, manganese, vitamins A, D, E, C, B₁, B₂, B₆, B₃, pantothenic acid and folic acid. Other essential micronutrients may also be added. Thus for example a parenteral nutrition solution might typically contain alanine, arginine, aspartic acid, cysteine and/or cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, L-methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, dextrose, sodium, potassium, calcium, chloride and magnesium and might have
50 added thereto, before administration, further minerals, e.g. sources for phosphate, copper, iron, manganese, zinc, fluoride, and iodide. Such a parenteral nutrition solution can be made up for example from Vamin Glucose and Ped-EI (both available from KabiVitrum Ltd. of Uxbridge, United Kingdom).

Solutions for short term intravenous fluid and nutrition support around the times of surgical or other procedures which may temporarily prevent oral nutrition typically include glucose in some form of

physiologically acceptable saline or buffer solution.

Neither the short or long term types of parenteral nutrition solution contain essential fatty acids even though where the patient is receiving only parenteral alimentation essential fatty acid deficiency may develop rapidly for at least three reasons: (1) no essential fatty acids are being taken in orally, (2) the parenteral solutions tend to block mobilization of lipids from body stores, so reducing the ability to make use of the body's own content of essential fatty acids, and (3) the high glucose intake in particular tends to inhibit 6-desaturation of the essential fatty acids linoleic acid and alpha-linolenic acid. 6-desaturation within the body is required if these essential fatty acids are to exert their full nutritional effects.

As mentioned above, essential fatty acids must normally be administered in the form of lipid emulsions, usually containing linoleic acid with or without alpha-linolenic acid. Some specialist emulsions, especially for use in paediatrics, may also contain 6-desaturated fatty acids such as the n-6 essential fatty acid gamma-linolenic acid and the n-3 essential fatty acid eicosapentaenoic acid. Such emulsions are not free of side effects and there is particular concern about their effects on the lungs of premature infants. Typical essential fatty acid emulsions for parenteral nutrition are for example the Intralipid products of KabiVitrum Ltd.

As mentioned above, conjoint administration of lithium salts and of polyunsaturated fatty acids has been proposed for the treatment of disorders believed to be associated with prostaglandin imbalance and in EP-A-234733 orally administrable capsules containing lithium gamma-linolenate and/or lithium eicosapentaenoate for use in the treatment of Alzheimer's disease are proposed. There has however been no suggestion that any particular benefit in terms either of drug delivery or of therapeutic efficacy might arise from the use of lithium-polyunsaturated fatty acid salts and indeed there has been no suggestion that administration of such salts may have any therapeutic effect beyond that expected for conjoint administration of a lithium salt and of a polyunsaturated fatty acid. Furthermore, as discussed below, the major benefit of such use is not achieved on oral administration unless the salts are administered in which delays release until after the stomach is passed.

We have now found that the lithium salts of polyunsaturated fatty acids have surprisingly beneficial physicochemical properties which make them particularly suitable compounds for use in the administration of lithium in lithium therapy or for the administration of polyunsaturated fatty acids in polyunsaturated fatty acid therapy.

In particular we have found that, while most physiologically tolerable lithium salts are not readily lipid soluble and most polyunsaturated fatty acids are not readily water-soluble, lithium salts of polyunsaturated fatty acids surprisingly are crystalline solids at ambient temperature which are highly soluble in both water and alcohol. Consequently these properties particularly facilitate preparation of pharmaceutical and other compositions using the salts and the salts may be used to promote lithium and/or polyunsaturated fatty acid uptake following administration, especially where movement of lithium and/or polyunsaturated fatty acid from an aqueous phase to a lipid phase or vice versa may be desirable. Thus, for example, the lithium salts conventionally used in lithium therapy (which, as mentioned above, are not readily lipid soluble) may have difficulty entering primarily lipid environments so presenting problems where such entry (e.g. penetration into cells, into the skin or across the blood-brain barrier) is desirable, whereas entry of lithium into such lipid environments will be facilitated for lithium salts of the polyunsaturated fatty acids.

Equally, the relatively poor water solubility of the conventionally administered polyunsaturated fatty acids presents problems when attempting to ensure an even distribution of the fatty acid through both the intravascular and extravascular compartments of the extracellular fluid or when attempting to administer polyunsaturated fatty acids enterally (especially in patients with lipid malabsorption) or parenterally, and particularly intravenously, or when administering polyunsaturated fatty acids, topically in a cosmetically acceptable aqueous base, and these problems may be reduced by administering the acid as its water-soluble lithium salt.

Thus viewed from one aspect the invention provides a pharmaceutical composition comprising a lithium salt of a C_{18-22} polyunsaturated fatty acid having at least two unsaturated carbon-carbon bonds (said salt being referred to hereinafter as a $Li(C_{18-22} \text{ PUFA})$ salt) together with at least one physiologically acceptable excipient or carrier material, with the proviso that where said composition is in a solid form adapted for oral administration into the stomach in the treatment of Alzheimer's disease said lithium salt therein is provided with a gastric juice resistant release delaying coating. Preferred compositions include compositions for combatting enveloped viruses and diseases associated therewith and for combatting conditions responsive to lithium and/or C_{18-22} PUFA therapy.

Viewed from a further aspect the invention also provides the use of a $Li(C_{18-22} \text{ PUFA})$ for the manufacture of a therapeutic agent for the treatment of conditions responsive to lithium and/or C_{18-22} PUFA therapy with the proviso that where the agent is to be in a solid form adapted for oral administration into the

15 aspect the invention also provides a method of treatment of the human or animal body to combat conditions responsive to lithium and/or C_{18-22} PUFA therapy, said method comprising administering to said body an effective amount of a $Li(C_{18-22}PUFA)$, with the proviso that where the $Li(C_{18-22}PUFA)$ salt is administered orally into the stomach for the treatment of Alzheimer's disease it is provided with a gastric juice resistant coating.

20 Viewed from a yet still further aspect the invention also provides a method of treatment of the human or animal body to combat conditions responsive to lithium and/or C_{18-22} PUFA therapy, said method comprising administering to said body an effective amount of a $Li(C_{18-22}PUFA)$, with the proviso that where the $Li(C_{18-22}PUFA)$ salt is administered orally into the stomach for the treatment of Alzheimer's disease it is provided with a gastric juice resistant coating.

25 When administered orally into the stomach, due to the pH of the stomach contents, $Li(C_{18-22}PUFA)$ salts are liable to dissociate so reducing the effect of the lithium and PUFA entities of enhancing each other's transferability across aqueous/lipid phase boundaries and thus for oral administration according to the invention the $Li(C_{18-22}PUFA)$ salt is most preferably presented in a manner adapted to minimize dissociation in the stomach, e.g. by provision with an enteric, i.e. gastric juice resistant, coating or casing or by administration by tube, e.g. as a solution, directly into the intestines. Suitable enteric coated compositions thus include capsules or tablets provided with an enteric coating of an acrylate (such as the enteric

30 Eudragit coating materials produced by Röhm GmbH), cellulose acetate phthalate or other appropriate material which serves to delay active substance release until the composition reaches the intestines.

Lithium therapy has hitherto been performed under a constraint arising from the toxicity of lithium. However where the therapy requires transfer of lithium into or through a lipid phase, e.g. through cell walls or across the blood-brain barrier, using $Li(C_{18-22}PUFA)s$ it may be possible to deliver lithium ions to

35 particular sites at concentrations previously attainable only at unacceptably toxic lithium dosages.

Thus, for example, in antiviral therapy as the C_{18-22} PUFA)s are themselves known to possess virucidal activities, the C_{18-22} PUFA counterion not only will serve to target the virucidal lithium ions on lipid-rich environments thus enabling localized build up of lithium ions at concentrations otherwise achievable only at

40 unacceptably toxic lithium dosage levels but it will also contribute to the overall virucidal efficacy of the composition.

The $Li(C_{18-22}PUFA)$ in the compositions of the invention is preferably the salt of an acid which has 2-6 carbon-carbon double bonds and suitable $Li(C_{18-22}PUFA)s$ include the lithium salts of linoleic acid, alpha-linolenic acid, gamma-linolenic acid, dihomogamma-linolenic acid, arachidonic acid, adrenic acid,

45 22:5n-6, 18:4n-3, 20:4n-3, eicosapentaenoic acid, 22:5n-3, docosahexaenoic (22:6n-3) acid, and mixtures of two or more such salts. Lithium salts of n-3 and n-6 C_{18-22} PUFA)s, especially 6-desaturated PUFA)s are particularly preferred and where the pharmaceutical compositions of the invention are for use as nutritional compositions or as nutritional supplements, it is preferred that they contain at least one lithium salt of a C_{18-22} PUFA in the n-3 series (e.g. 18:3n-3 (alpha linolenic acid), 18:4 n-3, 20:4 n-3, 20:5n-3, 22:5 n-3 and

50 22:6n-3) and at least one lithium salt of a C_{18-22} PUFA in the n-6 series (e.g. 18:2 n-6 (linolenic acid), 18:3n-6 (gamma-linolenic acid), 20:3n-6 (dihomogamma-linolenic acid), 20:4n-6 (arachidonic acid), 22:4n-6 (adrenic acid) and 22:5n-6). Lithium gamma-linolenate, which is a white solid at ambient temperature and is soluble in water and in alcohol in amounts in excess of 3g/100ml is especially preferred.

To optimize the targetting of the lithium ions onto lipid-rich sites, the compositions of the invention intended for use in lithium therapy preferably contain no further lithium salts than the $Li(C_{18-22}PUFA)$; there may however be conditions in the treatment of which it is desirable to present lithium both as a lipid

55 soluble salt and as a primarily water-soluble salt.

The nature of the carrier material or excipient in the compositions of the invention will of course depend

on the end use to which the composition is to be put.

The compositions of the invention may conveniently comprise the $\text{Li}(\text{C}_{18-22}\text{PUFA})$ incorporated into a solid, liquid or aqueous carrier medium and the pharmaceutical compositions may be in forms suitable for topical, enteral, oral, rectal, vaginal, or parenteral (e.g. intravenous, subcutaneous, intramuscular or intravascular) administration to the human or animal body. The compositions, methods and uses of the present invention are however especially suited to the oral, parenteral and topical and especially oral and intravenous, administration of $\text{Li}(\text{C}_{18-22}\text{PUFA})$ salts. The pharmaceutical and disinfectant compositions are particularly suited respectively for oral or parenteral administration or for the topical treatment of inanimate surfaces or materials, such as kitchen, bathroom, toilet or surgery surfaces or surgical or dental equipment.

For the treatment of inanimate surfaces, the disinfectant compositions of the invention particularly preferably have as a carrier a substrate web impregnated with the $\text{Li}(\text{C}_{18-22}\text{PUFA})$. Thus, the disinfectant compositions of the invention may for example comprise a liquid or powder disinfectant base incorporating the $\text{Li}(\text{C}_{18-22}\text{PUFA})$, optionally together with further biocidal, e.g. virucidal, and/or lipophilic components, optionally carried by a web substrate. The pharmaceutical compositions of the invention may also if desired be incorporated into a web substrate. Thus a pharmaceutical composition may advantageously comprise a dressing with impregnated therein a $\text{Li}(\text{C}_{18-22}\text{PUFA})$ salt. Such dressings may be used for application to skin lesions with or without occlusion.

Where the composition of the invention comprises a web substrate, such as for example a cellulosic tissue or a woven or non-woven absorbent web, the substrate may be wet or dry according to the desired end use.

For external topical application to human or animal tissue, or for anal or vaginal application, the compositions of the present invention will generally be in the form of gels, creams, ointments, sprays, soaps, lotions, shampoo, emulsions or douches, or other cosmetic or skin or hair care formulations, and the compositions may particularly suitably contain as a carrier a further lipophilic component, e.g. a lipid or a lipid solvent, to enhance the lipid targeting property of the composition. The $\text{Li}(\text{C}_{18-22}\text{PUFA})$ salts are likely to prove particularly valuable for application to the skin because of the rich lipid content of the skin and the need for agents acting on the skin to move easily from lipid to aqueous phases and vice versa. These water soluble $\text{Li}(\text{C}_{18-22}\text{PUFA})$ salts thus enable essential fatty acids to be delivered to the skin in compositions which are particularly cosmetically acceptable and do not feel unduly greasy or oily.

As the optional further lipophilic component for the compositions of the invention, particular mention may be made of the polyunsaturated fatty alcohols, especially the alcohol analogues of the $\text{C}_{18-22}\text{PUFA}$ s. These alcohols are especially preferred as carriers in the compositions of the invention, not only because of the solubility within them of the $\text{Li}(\text{C}_{18-22}\text{PUFA})$ s but also because they themselves are powerful anti-viral agents.

Other suitable lipophilic components include free polyunsaturated fatty acids (e.g. $\text{C}_{18-22}\text{PUFA}$ s) or other derivatives thereof, such as esters (e.g. C_1-4 alkyl esters such as ethyl esters), amides and glycerides (e.g. mono-, di- and tri-glycerides). Particularly suitable as triglycerides are those derived from evening primrose oil, an oil containing gamma-linolenic acid and linoleic acid. Other vegetable oils which may be used as the source for suitable $\text{C}_{18-22}\text{PUFA}$ s or their derivatives include cotton seed, soybean, peanut, corn, safflower, sunflower seed, poppy seed, linseed, perilla, blackcurrant seed and borage seed oils. Fish oils may also be used.

For oral or rectal administration, the pharmaceutical compositions of the invention may be formulated using conventional pharmaceutical carriers and excipients, e.g. in the form of tablets, coated tablets, syrups, suppositories, capsules, powders, suspensions, emulsions, sprays, etc. As discussed above, since the $\text{Li}(\text{C}_{18-22}\text{PUFA})$ salts may dissociate at the normal pH of the stomach contents (but not at the pH of intestinal contents or of other body fluids), oral administration forms will particularly preferably have the $\text{Li}(\text{C}_{18-22}\text{PUFA})$ provided with an enteric coating to delay release of the $\text{Li}(\text{C}_{18-22}\text{PUFA})$ until it has passed through the stomach. Thus enteric coated capsules or tablets are especially preferred. Solutions or suspensions for administration by enteral tube or for rectal administration are also preferred.

For injection, the pharmaceutical compositions of the invention are preferably formulated as sterile solutions, emulsions or suspensions, e.g. in water for injections, or in solutions in a lipid or lipid solvent, again preferably also including further lipophilic and/or virucidal components. To enhance further the targeting of the compositions onto lipid-rich zones of the body, the $\text{Li}(\text{C}_{18-22}\text{PUFA})$ salts may optionally have a carrier in liposome, artificial chylomicron or micelle form.

The pharmaceutical compositions of the invention in parenterally administrable form may be used with particular advantage in parenteral alimentation. Thus parenterally administered $\text{Li}(\text{C}_{18-22}\text{PUFA})$ s may be used as a means of supplying the essential fatty acids in parenteral alimentation or to prevent or treat essential fatty acid deficiency. Accordingly pharmaceutical compositions according to the invention may be

in the daily lithium dose when essential fatty acids are given parenterally as lithium salts. Since lithium has been shown to stimulate the production of white blood cells, especially in situations where their levels are depressed by radiation or chemotherapy for malignant tumours, the administration of Li(C₁₈₋₂₂ PUFA) salts in this way could have other desirable effects.

25 The compositions of the invention, in sterile solution suspension or emulsion form, may also if desired be used for wound irrigation, e.g. during surgery where there is a risk of transfer of viral infection.

In the case of compositions for the treatment of inanimate surfaces, after application the compositions according to the invention may be removed or they may be left, e.g. as a prophylactic coating. Thus for example compositions according to the invention may be applied to condoms or other sexual devices and
30 viewed from another aspect the invention provides sexual appliances, such as barrier contraceptives, e.g. condoms, film and spray contraceptives, provided with a coating of or impregnated with a virucidal composition according to the invention, whereby to reduce the risk of sexual transmission of viral infection. In such cases, the carrier for the Li(C₁₈₋₂₂ PUFA) is particularly suitably a cream, gel, oil or emulsion.

Viewed from a yet further aspect, the present invention provides a process for the preparation of a
35 composition according to the invention, said process comprising obtaining a Li(C₁₈₋₂₂ PUFA) salt and subsequently incorporating said salt into at least one sterile excipient or carrier material, preferably including a C₁₈₋₂₂ polyunsaturated fatty alcohol, or an ester, amide or glyceride of a C₁₈₋₂₂ polyunsaturated fatty acid.

Besides their utility in conventional lithium and C₁₈₋₂₂PUFA therapies, the compositions of the present
40 invention are generally suitable for use in combatting or inactivating lipid-enveloped viruses, such as for example herpetic, pox and wart viruses and other viruses producing pathological effects on the skin, and especially, sexually transmittable viruses, including viruses transmitting acquired immune deficiency syndrome.

Thus, viewed from a further aspect, the invention provides a method of combatting transfer of lipid-
45 enveloped viruses comprising the surface application of, or the therapeutic or prophylactic treatment of a human or animal body with, a Li(C₁₈₋₂₂ PUFA), preferably by application of a virucidal composition according to the invention or a sexual appliance according to the present invention. In one particularly preferred embodiment, the method of the invention is a method of inhibiting the transmission of sexually transmitted diseases associated with lipid-enveloped viruses, said method comprising applying a composi-
50 tion or appliance according to the invention to inanimate or external body surfaces susceptible to contact with body fluids.

Viewed from a yet further aspect, the invention also provides the use of a Li(C₁₈₋₂₂ PUFA) for the manufacture of a therapeutic or prophylactic agent or device for use in a method of combatting lipid-enveloped viruses, and especially a method of inhibiting transmission of such viruses between humans or
55 animals or between cells in the human or animal body.

The concentration of the Li(C₁₈₋₂₂ PUFA) in the compositions of the invention will of course depend upon the physical nature of the composition as well as on its desired end use. However, for compositions for application or administration to the human body the concentration may conveniently be such that each

day or on each application or administration the body receives 1 mg to 100 g of the $\text{Li}(\text{C}_{18-22} \text{ PUFA})$, preferably 100 mg to 10 g, most preferably 200 mg to 1 g.

In the case of orally or parenterally administrable compositions, the compositions are preferably administered at a daily or one-off dosage of the $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ of 1 to 100,000 mg, especially 1-50,000 mg, preferably 100-10,000 mg, conveniently in dosage units of 50, 100, 250, 500 or 1000 mg. For topical administration, $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ concentrations by weight of 0.001 to 50%, for example from 0.01 to 30%, preferably 0.1 to 5%, may be appropriate.

As mentioned above lithium has long been known to have various therapeutic effects in the treatment of certain diseases and ailments. Nonetheless lithium treatment has often been accompanied by a number of side effects related to dosage and degree of accumulation and medical texts have advised that lithium should be administered under close medical supervision. It was thus with surprise that we found that significantly depressed lithium plasma levels, relative to those of healthy subjects, are associated with a number of ailments and diseases, in other words that lithium appears to be an essential trace element.

Thus in healthy subjects lithium plasma levels may generally be in excess of 0.04 mM/l, whereas in subjects suffering from atopic eczema or seborrheic dermatitis mean plasma levels of below 0.025 mM/l are found. Alcoholics, patients with psoriasis, candidiasis, pityriasis and other fungal skin infections and sufferers from combination skin similarly exhibit depressed lithium plasma levels. (Combination skin is a troublesome and unsightly complaint manifested by excessive greasiness in certain skin areas, such as the forehead and the nose, and excessive dryness in other skin areas, such as the sides of the face).

In our copending British Patent Application No. 8719988, filed 25 August 1987 whose disclosures are incorporated herein by reference, lithium containing nutritional supplements for combatting conditions associated with essential chemical deficiency are described. For such supplements, which for the purposes of the claims of the present application are regarded as pharmaceutical compositions, it will be highly advantageous to incorporate the lithium in the form of its salt with a C_{18-22} polyunsaturated fatty acid, especially where the supplement is in the form of a topically administrable composition, e.g. a cream, gel or ointment, a parenterally administrable composition, e.g. an aqueous solution, or an orally administrable composition, e.g. tablets or capsules and, particularly, orally administrable compositions in which the lithium salt is provided with gastric juice resistant release delaying coating. Thus in one preferred embodiment of the invention the pharmaceutical composition of the invention takes the form of a nutritional supplement.

Such nutritional supplements, which most preferably are sterile, may be in a form adapted for enteral, parenteral or topical administration, but most preferably will be in a form adapted for oral ingestion. Liquid preparations made with sterile or deionized water are particularly preferred. However, in another preferred embodiment the nutritional supplement may take the form of dietary supplement, such as a foodstuff. The nutritional supplement may alternatively be in a conventional pharmaceutical dosage form adapted for administration to the gastrointestinal tract.

In this regard, forms such as tablets, coated tablets, capsules, powders, drops, suspensions, solutions, syrups and suppositories deserve particular mention. Nevertheless as lithium nutritional supplementation may be achieved by parenteral or topical administration, for example by injection or by topical application (e.g. of an ointment, lotion, cream, paste or gel or the like), or by transdermal iontophoretic delivery, the nutritional supplement may be in the form of a composition adapted for one of these administration modes.

Where the nutritional supplement is prepared in a conventional pharmaceutical dosage form it may of course also contain conventional pharmaceutical carriers or excipients.

For oral administration, the nutritional supplement may conveniently take the form of a foodstuff, for example a food or drink mix, into which a $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ salt is incorporated. The nutritional supplement may particularly suitably be in the form of a so-called "complete" foodstuff, analogous to those which are prepared to serve as the major or sole source of nutrition for example for people wishing to lose weight, for post-operative patients, for elderly patients, for convalescents, or for individuals with specific dietary needs (e.g. patients with diabetes, coeliac disease or cystic fibrosis). For most people however a lithium supplemented foodstuff will preferably be of a type that is ingested daily in similar quantities, and for this reason the supplement will particularly conveniently comprise the $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ salt and a cereal or legume foodstuffs base. In an especially preferred embodiment, the nutritional supplement may be in the form of a breakfast cereal. In a preferred alternative, however, the nutritional supplement may take the form of a lithium-containing multi-vitamin/multi-mineral preparation, for example in the form of tablets, capsules, or drops, especially enteric coated tablets or capsules. In this regard, compositions are especially preferred which contain the $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ salt together with sources of one, some or all of the vitamins and the other essential elements, for example selected from vitamins A, B₁, B₂, B₃, B₆, B₁₂, C, D and E and calcium, copper, zinc, manganese and iron. In another embodiment, the $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ salt may be incorporated into an enteral alimentation solution. The nutritional supplement may however contain the Li-

For topical administration, the nutritional supplement will again preferably be in a form adapted for regular application in substantially similar quantities and thus the Li(C₁₈₋₂₂ PUFA) salt may particularly conveniently be incorporated within cosmetics, such as facial creams and ointments and the like.

5 The lithium content in the nutritional supplement will be selected according to the nature of the supplement and its administration route but in general will be within the range 1 ppb to 30% by weight of lithium, preferably 1 ppm to 20% lithium, especially preferably 0.001 to 10% lithium and particularly preferably up to 1% lithium. Obviously, where the nutritional supplement is in the form of a complete foodstuff, the lithium content will be towards the lower ends of the ranges specified above, for example it
10 may conveniently be in the range 1 ppb to 10 ppm, preferably 10 ppb to 1 ppm. Thus, for example in complete foods which might be administered in a dose of 500g/day, a lithium content of 5mg might be contemplated. More particularly, the daily dosage will generally be such that the adult body receives from 1 microgram to 50 mg, preferably 1 to 10 mg, of lithium per day, and it will preferably be such as to maintain the lithium plasma level above 0.04 mM/L.

15 In one particularly preferred embodiment therefore the pharmaceutical composition of the invention takes the form of a nutritional supplement comprising a foodstuffs base with included therein, preferably provided with a gastric juice resistant release delaying coating, a Li(C₁₈₋₂₂ PUFA) in a concentration such that said supplement contains from 1 ppb to 1% by weight of lithium. Nutritional supplements prepared from sterilized or deionized base materials would be particularly preferred.

20 In another preferred embodiment the nutritional supplement comprises a sterile composition containing a Li(C₁₈₋₂₂ PUFA) salt, preferably provided with a gastric juice resistant release delaying coating, together with four or more, preferably eight or more, vitamins or minerals, for example essential vitamins or minerals selected from the group consisting of vitamins A, B₁, B₂, B₃, B₆, B₁₂, C, D and E and physiologically tolerable calcium, copper, zinc, manganese and iron compounds.

25 Such nutritional supplements may be used to combat a wide range of conditions associated with essential chemical deficiency, in particular conditions which appear to be associated with immune system malfunction and especially conditions such as combination skin, atopic eczema, psoriasis, seborrheic dermatitis, candidiasis, pityriasis, skin fungal infections and conditions associated with alcoholism, and the uses and methods of the invention are deemed to relate to the treatment of such conditions as well as the
30 conditions mentioned earlier herein.

The compositions of the invention may of course contain further ingredients, such as for example conventional pharmaceutical or topical disinfectant formulation aids, e.g. emulsifiers, extenders, flavours, colouring agents, surfactants, pH adjusting agents, ointment bases, gelling agents, propellants, stabilizers and the like. The compositions may also contain other physiologically active agents.

35 The present invention will now be illustrated further by the following non-limiting Examples in which all percentages, ratios and parts are by weight unless otherwise specified:

Example 1

40

Orally administrable capsules

45 Appropriately sized hard or soft gelatin capsules are each filled with 250, 500 or 1000 mg of lithium gamma-linolenate and optionally are provided with an enteric coating.

Alternatively, lithium eicosapentaenoate, lithium arachidonate, or lithium dihomo-gamma-linolenate may be used in place of the lithium gamma-linolenate or a combination of two or more of these four lithium salts may be used.

50

Example 2

55

Orally administrable capsules

Appropriately sized hard or soft gelatin capsules are each filled with 100 mg of lithium eicosapentaenoate and 400 mg of gamma-linolenyl alcohol and optionally are provided with an enteric coating.

Example 3

10

Orally administrable capsules

Appropriately sized hard or soft gelatin capsules are each filled with 50 mg of lithium arachidonate and 250 mg of dihomo-gamma-linolenyl alcohol and optionally are provided with an enteric coating.

Example 4

20

Orally administrable capsules

Appropriately sized hard or soft gelatin capsules are each filled with 50 mg of lithium eicosapentaenoate, 50 mg of lithium arachidonate and 400 mg of gamma-linolenyl alcohol and optionally are provided with an enteric coating.

Example 5

30

Orally administrable capsules

Appropriately sized hard or soft gelatin capsules are each filled with 50 mg of lithium gamma-linolenate, 50 mg of eicosapentaenyl alcohol and 100 mg of dihomo-gamma linolenic acid and optionally are provided with an enteric coating.

Example 6

Orally administrable capsules

45

Appropriately sized hard or soft gelatin capsules are each filled with 50 mg of lithium arachidonate, 50 mg of docosahexaenyl alcohol (22:6n-3) and 220 mg of evening primrose oil-derived triglycerides and optionally provided with an enteric coating.

50

Example 7

Parenterally administrable solutions

55

A solution is prepared by dissolving 5g of lithium gamma-linolenate, alone or with 5g of lithium arachidonate, lithium eicosapentaenoate, or lithium docosahexaenoate, in 500ml of saline or glucose

Example 810 Solutions for enteral or rectal administration

A solution is prepared by dissolving 5g of lithium gamma-linolenate (or another $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ or a combination of $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ s) in 100ml of an enteral or rectal administration solution.

15

Example 920 Parenterally administrable emulsions

An emulsion is prepared by emulsifying one volume of an oil phase comprising 5 g of lithium eicosapentaenoate and 5 g of lithium gamma-linolenate dissolved in 100 g of corn oil with ten volumes of an aqueous phase comprising a 1% lecithin and 2% glycerol aqueous solution.

25

Example 10

30

Parenterally administrable emulsions

An emulsion is prepared by emulsifying one volume of an oil phase comprising 10 g of lithium dihomogamma-linolenate and 5 g of eicosapentaenyl alcohol dissolved in 100 g of corn oil with seven volumes of an aqueous phase comprising a 1.5% lecithin and 2% glycerol aqueous solution.

35

The eicosapentaenyl alcohol may if desired be replaced by gamma-linolenyl alcohol or any of the other alcohol analogues of the $\text{C}_{18-22} \text{ PUFA}$ s. Similarly other $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ salts may be used in place of lithium dihomogamma-linolenate.

40

Example 1145 Orally administrable tablets

Tablets are prepared in a conventional manner from lithium gamma-linolenate, arachidonate, eicosapentaenoate or any other $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ admixed with a physiologically acceptable tableting aid. The mixture is compressed to yield tablets each containing 500 mg of the lithium salt. These tablets may then if desired be provided with a gastric juice resistant enteric coating.

50

Example 12

55

Cosmetic composition

5 Cosmetic compositions, e.g. creams, lotions or the like, may be prepared by mixing into a conventional
 5 cosmetic composition sufficient lithium gamma-linolenate and lithium eicosapentaenoate to produce a
 composition containing containing 3% lithium gamma-linolenate and 1% lithium eicosapentaenoate. Where
 the composition contains no aqueous, alcoholic or lipid solvents, the lithium salts are preferably used in
 finely divided form.

10

Example 13Skin and hair care compositions

15

Skin and hair care compositions, such as lotions, creams or shampoos, may be prepared by mixing into
 a conventional skin or hair care composition sufficient lithium gamma-linolenate and lithium eicosapen-
 taenoate to yield a composition containing 5% lithium gamma-linolenate and 3% lithium eicosapentaenoate.

20

Example 1425 Surface disinfecting composition

A surface disinfecting composition is prepared by dissolving in 100 g of 70% ethanol 1 g of lithium
 gamma-linolenate and 1 g of eicosapentaenyl alcohol. This composition may be absorbed into cellulosic
 30 tissues which may then be packed in air-and liquid-tight plastics-lined foil or paper sachets.

Example 15

35

Surface disinfecting composition

A surface disinfecting composition is prepared by emulsifying a mixture of 0.5% lithium arachidonate in
 40 water. The composition may be absorbed into tissues as described in Example 14.

Example 16

45

Surface disinfecting composition

A surface disinfecting composition is prepared by emulsifying one volume of an oil phase comprising 1
 50 g of lithium dihomogamma-linolenic acid, 1 g of arachidonyl alcohol and 15 g of corn oil with ten volumes
 of an aqueous phase comprising a 2.5% lecithin and 2% glycerol aqueous solution.

Example 17

55

Surface disinfecting compositions

5 A surface disinfecting composition is prepared by dissolving 5 parts of lithium gamma-linolenate and 5 parts of lithium arachidonate in 90 parts of water.

Example 18

10

Surface disinfecting compositions

15 A surface disinfecting composition is prepared by dissolving 2 parts of lithium eicosapentaenoate and 5 parts of gamma-linolenyl alcohol in 93 parts of water or of 70% ethanol.

Example 19

20

Foodstuffs Composition

25 A breakfast cereal, for use as a nutritional supplement, contains the following ingredients in each 30 g serving:

Vitamin A 4000 iU
Vitamin B₁ 1 mg
Vitamin B₂ 1mg
Vitamin C 50mg
30 Vitamin D 400 iU
Calcium carbonate 5mg
Lithium eicosapentaenoate 20mg
Rolled oats ad30 g

35

Example 20

Multi-Vitamin/Mineral Tablet

40

Multi-vitamin/mineral tablets for daily ingestion each contain the following ingredients:

Vitamin A 4000 iU
Vitamin B₁ 1.5 mg
45 Vitamin B₂ 1 mg
Vitamin B₆ 1 mg
Vitamin B₃ 2 mg
Vitamin C 40 mg
Vitamin D 400 iU
50 Vitamin E 4 mg
Calcium carbonate 5 mg
Lithium gammalinolenate 50 mg
Iron (II) carbonate 10 mg
Manganese sulphate 1 mg
55 Nicotinamide 15 mg
Tableting base ad450 mg

The tablet components are mixed and compressed to form biconvex tablets which are then coated in a conventional manner. If desired the lithium gamma-linolenate may be precoated with a gastric juice resistant release delaying coating (e.g. a Eudragit coating) or it may be incorporated into a matrix of such a coating material, ground to a powder and then incorporated into the multi-vitamin/mineral tablet.

5

Example 21

10 Cosmetic Composition

A night cleansing composition is formed by mixing three parts by weight of lithium gamma-linolenate with ninety seven parts by weight of a cosmetic night cleansing cream base.

15

Example 22

20 Body Lotion

A body lotion is formed by mixing 3 parts by weight of lithium gammalinolenate with 96 parts by weight of a body lotion base.

25

Example 23

30 Face Cream

A day face cream is formed by mixing 4 parts by weight of lithium gammalinolenate with 96 parts by weight of a face cream base.

35

Example 24

40 Complete Foodstuff

A complete foodstuff, particularly suited for administration to geriatric or convalescent subjects at a daily dosage of about 500 g/day, is prepared by admixing 70mg of lithium gammalinolenate together with 45 500g of a complete foodstuffs composition containing all other major essential nutrients.

Example 25

50

Parenteral Nutrition Solution

A solution for parenteral nutrition is prepared by dissolving 1g of lithium linoleate in 500ml of an aqueous parenteral nutrition solution. The aqueous nutrition solution used may for example be Vamin N or Vamin Glucose, optionally admixed about 13:1 by volume with Ped-El.

55

lithium alpha-linolenate, e.g. by
the 1g of lithium linoleate.

20

Example 28

25 Injection solutions for addition to parenteral nutrition fluids

Solutions are prepared containing:

- (a) lithium linoleate 1g
30 ethanol/0.9% saline (50/50 by volume) 10 ml
(b) lithium linoleate 1g
lithium alpha-linolenate 0.3g
ethanol/0.9% saline (50/50 by volume) 10ml
(c) lithium linoleate 1g
35 lithium alpha-linolenate 0.3g
lithium gamma-linolenate 0.3g
lithium eicosapentaenoate 0.3g
ethanol/0.9% saline (50/50 by volume) 10ml

40 These solutions are each filled into vials under aseptic conditions and sealed therein. The contents of such vials may be added to 100ml or 500ml or other sizes of bottles of aqueous fluids for parenteral nutrition which do not already contain essential fatty acids.

In this Example, in place of the $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ salts specified other lithium salts may instead be used, for example salts of n-6 PUFA)s such as lithium dihomogamma-linolenate, lithium arachidonate, lithium adrenate and lithium docosapentaenoate(22:5n-6) and salts of the n-3 PUFA)s such as lithium stearidonate,
45 lithium 20:4n-3, lithium docosapentaenoate (22:5n-3) and lithium docosahexaenoate (22:6n-3).

Example 29

50

Parenteral solutions

55 5g of lithium gamma-linolenate or lithium eicosapentaenoate (or another $\text{Li}(\text{C}_{18-22} \text{ PUFA})$ salt) is dissolved in 500 ml of physiological saline containing 5% glucose and the solution is filled into bottles, flasks or bags under aseptic conditions. Such containers may then be used for parenteral administration, e.g. by infusion, of the $\text{Li}(\text{C}_{18-22} \text{ PUFA})$.

Example 30Injection solutions

5

3g of lithium gamma-linolenate (or another $\text{Li}(\text{C}_{18-22}$ PUFA) salt is dissolved in 10ml of an ethanol/0.9% saline (50/50 by volume) mixture. The solution is filled into a vial under sterile conditions. The solution may be used for administration of the $\text{Li}(\text{C}_{18-22}$ PUFA) salt in the treatment of disease.

10

Example 31Solubility

15

The change in lithium and PUFA solubilities conferred by formation of the $\text{Li}(\text{C}_{18-22}$ PUFA) salts is illustrated by the following experiments.

(A) Equimolar amounts of lithium gamma-linolenate (500mg) and lithium chloride (128.4mg) were dissolved in 50 ml distilled water. Each 50ml water contained 11.4mg lithium. Each aqueous solution was then shaken with 250ml of chloroform/methanol (2/1 by volume). The chloroform/methanol fraction was then separated off and evaporated to dryness under a stream of nitrogen. The mass of dry extract from the chloroform/methanol phase was weighed and its lithium content determined by flame photometry. The lithium content of the aqueous phase was also measured by flame photometry.

(B) 1g of pure gamma-linolenic acid was dissolved in 10 ml of chloroform/methanol (2/1 by volume). The resulting solution was then thoroughly shaken with 50 ml distilled water. The chloroform/methanol phase was then separated off and evaporated to dryness in a stream of nitrogen and the mass of dry extract was weighed.

The experiments were repeated five times and the ranges of results obtained are shown in the following tables:

Table I

35

| | <u>Percentage of total lithium in:</u> | |
|------------------|--|----------------------------------|
| | <u>Aqueous phase</u> | <u>Chloroform/methanol phase</u> |
| Lithium chloride | 95-91% | 1-5% |
| Lithium | | |
| gammalinolenate | 11-17% | 83-89% |

40

Table II

45

| | <u>Percentage of total fatty acid/ fatty acid salt* in:</u> | |
|----------------------|---|----------------------------------|
| | <u>Aqueous phase</u> | <u>Chloroform/methanol phase</u> |
| Gamma-linolenic acid | 2-9% | 91-98% |
| Lithium | | |
| gammalinolenate | 11-17% | 83-89% |

50

55

(*taken as equivalent to the percentage of lithium)

- at least two unsaturated carbon-carbon bonds together with at least one physiologically acceptable excipient or carrier material, with the proviso that where said composition is in a solid form adapted for oral administration into the stomach in the treatment of Alzheimer's disease said lithium salt therein is provided with a gastric juice resistant release delaying coating.
2. A composition as claimed in claim 1 adapted for oral administration and wherein said lithium salt is provided with a gastric juice resistant release delaying coating.
3. A composition as claimed in claim 1 in a form adapted for topical administration.
4. A composition as claimed in claim 1 in a form adapted for parenteral administration.
5. A composition as claimed in any one of claims 1 to 4 comprising said lithium salt in solution, suspension or emulsion in a physiologically acceptable sterile liquid.
6. A composition as claimed in claim 5 being a parenteral nutrition composition comprising at least one lithium salt of a n-3 C₁₈₋₂₂ polyunsaturated fatty acid and at least one lithium salt of a n-6 C₁₈₋₂₂ polyunsaturated fatty acid.
7. A composition as claimed in either one of claims 5 and 6 being a parenteral nutrition solution comprising in aqueous solution said lithium salt or salts and at least one further nutritional component selected from : vitamins, essential minerals and calorie sources.
8. A composition as claimed in any one of claims 1 to 5 in the form of a nutritional supplement.
9. A composition as claimed in claim 8 comprising a foodstuffs base with said lithium salt included therein in a concentration such that the lithium content of said composition is from 1 ppb to 1% by weight.
10. A composition as claimed in claim 8 comprising said lithium salt together with four or more vitamins or minerals selected from the group consisting of vitamins A, B₁, B₂, B₃, B₆, B₁₂, C, D and E and physiologically tolerable calcium, copper, zinc, manganese and iron compounds.
11. A composition as claimed in any one of claims 1 to 10 in dosage unit form containing 50-1000 mg of said lithium salt per dosage unit.
12. A disinfectant composition comprising a lithium salt of a C₁₈₋₂₂ polyunsaturated fatty acid together with at least one carrier material.
13. A composition as claimed in claim 12 further comprising at least one other biocidal agent.
14. A composition as claimed in any one of claims 1 to 13 containing from 0.1 to 5% by weight of said lithium salt.
15. A composition as claimed in any one of claims 1, 3, 5 and 11 to 14 comprising as a said carrier material a web substrate whereinto said lithium salt is impregnated.
16. A composition as claimed in any one of claims 1 to 15 comprising at least one lithium salt selected from the salts of lithium with linoleic acid, alpha-linolenic acid, gamma-linolenic acid, dihomogamma-linolenic acid, arachidonic acid, adrenic acid, 22:5n-6, 18:4n-3, 20:4n-3, eicosapentaenoic acid, 22:5n-3, and docosahexaenoic (22:6n-3) acid.
17. A composition as claimed in any one of claims 1 to 5 and 8 to 16 comprising a lipid or lipid solvent carrier material.
18. A composition as claimed in claim 17 wherein said lipid or lipid solvent comprises a C₁₈₋₂₂ polyunsaturated fatty alcohol or acid, or an ester, amide or glyceride thereof.
19. Use of a lithium salt of a C₁₈₋₂₂ polyunsaturated fatty acid for the manufacture of a therapeutic agent for use in the treatment of conditions responsive to lithium and/or C₁₈₋₂₂ polyunsaturated fatty acid therapy, with the proviso that where the agent is to be in a solid form adapted for oral administration into the stomach in the treatment of Alzheimer's disease said lithium salt therein is provided with a gastric juice resistant release delaying coating.
20. Use as claimed in claim 19 for the manufacture of a therapeutic agent for use in parenteral nutrition or in the treatment of a condition selected from: essential fatty acid deficiency and conditions associated therewith; inflammatory and immunological disorders; psychiatric disorders; disorders associated with smooth muscle spasm; diabetes and complications associated therewith; cancers; alcoholism; combination skin; and cardiovascular disorders.

21. A method of combatting transfer of lipid-enveloped viruses comprising the surface application of a disinfectant composition as claimed in any one of claims 12 to 18.

22. A method as claimed in claim 21 for inhibiting transmission of sexually transmitted diseases which method comprises applying a composition as claimed in any one of claims 12 to 18 to inanimate or external
5 body surfaces susceptible to contact with body fluids.

23. A sexual appliance provided with a coating of or impregnated with a composition comprising a lithium salt of a C_{18-22} polyunsaturated fatty acid together with at least one physiologically acceptable excipient or carrier material.

24. An appliance as claimed in claim 23 being a barrier contraceptive.

10 25. Use of a lithium salt of a C_{18-22} polyunsaturated fatty acid for the manufacture of a therapeutic or prophylactic agent or device for use in a method of combatting lipid-enveloped viruses.

26. Use as claimed in claim 25 for the manufacture of a therapeutic or prophylactic agent or device for use in a method of inhibiting transmission of lipid-enveloped viruses between humans or animals or between cells in a human or animal body.

15 27. A process for the preparation of a composition as claimed in any one of claims 1 to 18, said process comprising obtaining a lithium salt of a C_{18-22} polyunsaturated fatty acid and subsequently incorporating said salt into at least one sterile excipient or carrier material.

20

25

30

35

40

45

50

55

12

EUROPEAN PATENT APPLICATION

21 Application number: 88303560.2

51 Int. Cl.4: **A 61 K 31/20**

22 Date of filing: 20.04.88

A 61 K 9/28

30 Priority: 27.04.87 GB 8709892
25.08.87 GB 8719988
29.01.88 GB 8802016

43 Date of publication of application:
02.11.88 Bulletin 88/44

84 Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

88 Date of deferred publication of search report:
26.04.89 Bulletin 89/17

71 Applicant: **EFAMOL HOLDINGS PLC**
Efamol House Woodbridge Meadows
Guildford Surrey GU1 1BA (GB)

72 Inventor: **Horrobin, David Frederick**
2e Cedar Lodge Lythe Hill Park
Haslemere Surrey (GB)

74 Representative: **Cockbain, Julian Roderick Michaelson**
et al
Frank B. Dehn & Co. European Patent Attorneys Imperial
House 15-19, Kingsway
London WC2B 6UZ (GB)

54 **Lithium salt-containing pharmaceutical compositions.**

57 The invention provides pharmaceutical and disinfectant compositions containing lithium salts of C₁₈₋₂₂ polyunsaturated fatty acids. The compositions may be used in the treatment of conditions responsive to lithium and/or polyunsaturated fatty acid therapy, in parenteral alimentation or food supplements or in surface disinfection to combat transmission of viral diseases.



DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int. Cl. 4) |
|----------|--|-----------------------|--|
| A | EP-A-0 068 854 (D.F. HORROBIN et al.) * Whole document * | 1-11, 14-20, 27 | A 61 K 31/20 A 61 K 9/28 |
| | -- | | |
| A | US-A-4 328 243 (D.F. HORROBIN et al.) * Whole document * | 1-11, 14-20, 27 | |
| | -- | | |
| A | FR-A-2 244 485 (F. ARIES) * Pages 1-3 * | 1-11, 14-20, 27 | |
| | -- | | |
| A | EP-A-0 115 419 (EFAMOL LTD) * Pages 8-10 * | 1-11, 14-20, 27 | TECHNICAL FIELDS SEARCHED (Int. Cl. 4) A 61 K 33/00 A 61 K 31/00 A 23 L 1/00 |
| | -- | | |

INCOMPLETE SEARCH

./.

The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.

Claims searched completely: 1-11, 14-20, 27

Claims searched incompletely:

Claims not searched: 21, 22

Reason for the limitation of the search:

Method for treatment of the human or animal
body by surgery or therapy (see Art. 52(4)
of the European Patent Convention).

Place of search
THE HAGUE

Date of completion of the search
03-11-1988

Examiner
GERLI

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another
document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or
after the filing date
D : document cited in the application
L : document cited for other reasons
& : member of the same patent family, corresponding
document



Application number

-2-

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | CLASSIFICATION OF THE APPLICATION (Int. Cl. 4) |
|-------------------------------------|---|-----------------------|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | |
| A | EP-A-192 367 (WARNER LAMBERT CO.) * Claims 10,12,15 * -- | 1-11, 14-20, 27 | |
| A | A. GOODMAN- GILMAN et al.: PHARMACOLOGICAL BASES OF THERAPEUTICS, Ed. 7, 1985, MacMillan, New York, US * Pages 426-431 * ----- | 1-11, 14-20, 27 | TECHNICAL FIELDS SEARCHED (Int Cl 4) |
| | | | |
| | | | |



CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

☐

All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.

☐

Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid.

namely claims:

☐

No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

X LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions.

namely:

1. Claims 1-11, 14-20, 27: Pharmaceutical preparation, use thereof and process
2. Claims 12, 13, 25, 26: Disinfectant, use thereof
3. Claims 23, 24: Sexual appliance, barrier contraceptive

☐

All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

☐

Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid.

namely claims:

☒

None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims.

namely claims: 1-11, 14-20, 27